What is HC Wainwright's Forecast for Insmed FY2028 Earnings?

Insmed Incorporated (NASDAQ:INSM - Free Report) - Analysts at HC Wainwright boosted their FY2028 earnings estimates for Insmed in a research report issued to clients and investors on Wednesday, June 11th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will earn $2.63 per share for the year, up from their previous forecast of $2.37. HC Wainwright has a "Buy" rating and a $120.00 price objective on the stock. The consensus estimate for Insmed's current full-year earnings is ($4.56) per share.

Other research analysts have also issued research reports about the stock. Mizuho increased their price target on shares of Insmed from $96.00 to $110.00 and gave the stock an "outperform" rating in a research report on Wednesday. Guggenheim reiterated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. Wells Fargo & Company increased their target price on Insmed from $107.00 to $119.00 and gave the stock an "overweight" rating in a report on Wednesday. The Goldman Sachs Group boosted their price target on Insmed from $100.00 to $112.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Bank of America upped their price target on Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a research report on Wednesday. One analyst has rated the stock with a sell rating and eighteen have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $104.81.

Insmed Stock Performance

INSM stock traded down $1.10 during trading on Thursday, reaching $96.88. 7,168,280 shares of the stock were exchanged, compared to its average volume of 2,164,849. Insmed has a twelve month low of $60.40 and a twelve month high of $99.84. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $17.65 billion, a P/E ratio of -17.33 and a beta of 0.80. The stock has a 50 day simple moving average of $70.73 and a 200-day simple moving average of $73.47.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company's revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.06) EPS.

Institutional Investors Weigh In On Insmed

Institutional investors and hedge funds have recently modified their holdings of the business. Cullen Frost Bankers Inc. grew its holdings in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares during the period. Elequin Capital LP bought a new position in shares of Insmed in the 4th quarter worth $28,000. Steward Partners Investment Advisory LLC grew its stake in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the period. NBC Securities Inc. acquired a new stake in shares of Insmed during the first quarter worth $49,000. Finally, V Square Quantitative Management LLC increased its holdings in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the last quarter.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 9,925 shares of the business's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $65.47, for a total transaction of $649,789.75. Following the completion of the sale, the insider now owns 86,596 shares in the company, valued at $5,669,440.12. The trade was a 10.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total value of $9,264,648.24. Following the completion of the transaction, the insider now owns 89,407 shares in the company, valued at approximately $8,352,401.94. This represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 262,166 shares of company stock valued at $20,585,587. Insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.